Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Ovagen

Not FDA approved

Short synthetic bioregulator peptide

Evidence score

14/ 100

Thin evidence

Very thin human evidence

Regulatory standing. Sold as a research chemical, not approved
Animal / preclinical only. Evidence is largely animal or in-vitro
No registered human trials. Nothing registered on ClinicalTrials.gov
No sources. Nothing cited to verify

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Ovagen is a short synthetic peptide marketed as a 'bioregulator,' a concept developed mainly by Russian researchers associated with Vladimir Khavinson. It is described as a tripeptide said to be aimed at liver and gastrointestinal tissue, with the proposed idea that such short peptides influence gene expression in target cells. This mechanism has not been clearly established.

What the evidence shows

Automatic summaryAnimal / preclinical

There are no registered human trials, and the roughly 23 published papers come largely from a small group of researchers, much of it lab or animal work, so effects in humans are unproven. It is not FDA-approved for any use.

This name is shared with unrelated compounds in public databases, so trial and paper counts are not shown here, and the evidence score counts no registered trials. Treat this profile as a starting point only.

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.